



(12) Translation of
European patent specification

(11) NO/EP 2688572 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/19 (2006.01)
A61K 31/573 (2006.01)
A61P 31/02 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.07.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.05.03
(86)	European Application Nr.	12759898.5
(86)	European Filing Date	2012.03.20
(87)	The European Application's Publication Date	2014.01.29
(30)	Priority	2011.12.15, SE, 1151196 2011.03.21, US, 201161454751 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Valcuria AB, Scheelevägen 2, 223 81 Lund, SE-Sverige
(72)	Inventor	DROTT, Kristina, Vallkärratorns Bygata 11, S-226 50 Lund, SE-Sverige RELANDER, Thomas, Rösträttsgatan 44, S-227 60 Lund, SE-Sverige
(74)	Agent or Attorney	Orsnes Patent ApS, Forskerparken 10, DK-5230 ODENSE, Danmark

(54)	Title	A PHARMACEUTICAL COMPOSITION COMPRISING A HDAC INHIBITOR AND A STEROID AND THE USE THEREOF
(56)	References Cited:	WO-A1-2008/083290 WO-A1-2009/062054 WO-A2-02/15921 WO-A2-2007/054719 US-A1- 2005 038 113 US-A1- 2006 229 237 P. S. BACHMANN ET AL: "Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition", BLOOD, vol. 116, no. 16, 20 July 2010 (2010-07-20), pages 3013-3022, XP055124426, ISSN: 0006-4971, DOI: 10.1182/blood-2010-05-284968 HELFAND BRIAN T ET AL: "Improvement in EEG and clinical function in pervasive developmental delay (PDD): Pharmacologic effects of monotherapy and combination therapy with valproic acid and prednisone", EPILEPSIA, vol. 39, no. SUPPL. 6, 1998, page 251, XP009179013, & ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY; SAN DIEGO, CALIFORNIA, USA; DECEMBER 6-9, 1998 ISSN: 0013-9580 KEN-ICHI KITAZOE ET AL: "Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma", INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 89, no. 1, 18 December 2008 (2008-12-18), pages 45-57, XP055128425, ISSN: 0925-5710, DOI: 10.1007/s12185-008-0226-9 TRAN THUYET ET AL: "Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting.", CANCER RESEARCH 15 MAY 2005, vol. 65, no. 10, 15 May 2005 (2005-05-15), pages 4431- 4441, XP055027176, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-04-2890 MORRISON VICKI A: "Evolution of R-CHOP therapy for older patients with diffuse large B-cell

lymphoma.", EXPERT REVIEW OF ANTICANCER THERAPY OCT 2008, vol. 8, no. 10, October 2008 (2008-10), pages 1651-1658, XP009179038, ISSN: 1744-8328
 Thomas M Habermann: "Recent advances in the treatment of B-cell lymphoma", F1000 medicine reports, 24 February 2009 (2009-02-24), XP055128577, England DOI: 10.3410/M1-13 Retrieved from the Internet: URL:<http://www.ncbi.nlm.nih.gov/pubmed/20948769> [retrieved on 2014-07-14]
 PETRA S BACHMANN ET AL.: 'Epigenic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition' BLOOD vol. 116, no. 16, 2010, pages 3013 - 3022, XP055124426
 K TED THURN ET AL.: 'Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer' FUTURE ONCOLOGY vol. 7, no. 2, 2011, pages 263 - 283, XP008159262

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En histon deacetylase (HDAC)-inibitor og et steroid for bruk i forbehandlingen av en sykdom valgt fra gruppen som består av diffus stor B-celle lymfom (DLBCL), follikulært lymfom, kronisk lymfatisk leukemi, T-celle lymfom og Hodgkins lymfom, hvori HDAC-inhibitoren velges fra en gruppe som består av valproinsyre, valproatseminatrium, natriumvalproat, magnesiumvalproat eller blandinger derav, og hvori steroidet velges fra gruppen som består av prednison, prednisolon, deksametason eller betametason.
5
2. En HDAC-inhibitor og et steroid for bruk ifølge krav 1, hvori HDAC-inhibitoren er valproinsyre og steroidet er prednison.
10
3. En HDAC-inhibitor og et steroid for bruk ifølge hvilket som helst av krav 1 til 2, hvori substansene kombineres i en farmasøytisk sammensetning, hvori sammensetningen er i form av granulater, pulver, tabletter, drasjéer, mikrokapsler, mikrogranulater eller brusende former.
15
4. En HDAC-inhibitor og et steroid for bruk ifølge krav 3, hvori substansene er i form av tabletter.
- 20 5. En HDAC-inhibitor og et steroid for bruk ifølge hvilket som helst av krav 1 til 2, videre i kombinasjon med et antistoff, monoklonalt antistoff eller funksjonelle fragmenter derav som binder til CD20.